AndreaBozzo/ceres-open-data-index huggingface dataset:
Seattle

Data tables consisting of Excel files with estimates, rates, relative standard errors, trends and confidence intervals, covering 2004-2011, for drug-related emergency department visits for the Seattle Metropolitan Statistical Area. Tables are provided for 10 topics (\"analytic categories\") which are defined in the \"Guide to Drug Abuse Warning Trend Tables,\"  a separate document.   Each table includes data for over 500 drugs, including illicit drugs, prescription and over-the-counter medications, dietary supplements, inhalants and alcohol. Includes total visits, gender, age group, race/ethnicity, outcome of visit, drug combinations, number of drugs involved in visit, drug frequency, and drugs confirmed by toxicology. Additional detail is provided for illicit drugs, psychotherapeutic drugs, central nervous system (CNS) drugs, respiratory drugs and cardiovascular drugs.
Payroll Based Journal Daily Nurse Staffing

The Payroll Based Journal (PBJ) Nurse Staffing and Non-Nurse Staffing datasets provide information submitted by nursing homes including rehabilitation services on a quarterly basis. The View Data link above includes the hours staff are paid to work each day, for each facility, aggregated by staff reporting category.  Examples of reporting categories include Director of Nursing, Administrative Registered Nurses, Registered Nursing, Administrative Licensed Practice Nurses, Licensed Practice Nurses, Certified Nurse Aides, Certified Medication Aides, and Nurse Aides in Training. There are also other non-nurse staff categories provided in the data such as Respiratory Therapist, Occupational Therapist, and Social Worker. The datasets also include a facility’s daily census calculated using the Minimum Data Set (MDS) submission.
Discordance between physical symptoms versus perception of severity by women with nausea and vomiting in pregnancy (NVP)

Background
          Nausea and vomiting in pregnancy (NVP) is a multifaceted condition that affects more than half of pregnant women and can range in severity from mild nausea to severe dehydration. Presently physicians evaluate mostly physical symptoms of NVP in trying to assess the severity of the condition. The objective of this study was to investigate how factors, other than the physical morbidity of nausea and vomiting, influence self-perception of NVP by affected women.
        
        
          Methods
          Five hundred women with NVP calling a 1–800 NVP Healthline were asked to rate their NVP severity and report their nausea duration and number of vomiting/retching episodes.
        
        
          Results
          Nausea and vomiting/retching correlated significantly but very poorly with self-assessment of NVP severity. There was also a correlation between nausea duration and vomiting/retching frequency however the correlations were weak and overall physical symptoms could only explain 14% of the variability of women's feelings and perceptions through multivariate analysis.
        
        
          Conclusions
          Physical symptoms weakly correlate with self-assessment of NVP severity. Other aspects of this condition, most probably psychosocial, influence women's perception of NVP severity.
On the probability of cost-effectiveness using data from randomized clinical trials

Background
          Acceptability curves have been proposed for quantifying the probability that a treatment under investigation in a clinical trial is cost-effective. Various definitions and estimation methods have been proposed. Loosely speaking, all the definitions, Bayesian or otherwise, relate to the probability that the treatment under consideration is cost-effective as a function of the value placed on a unit of effectiveness. These definitions are, in fact, expressions of the certainty with which the current evidence would lead us to believe that the treatment under consideration is cost-effective, and are dependent on the amount of evidence (i.e. sample size).
        
        
          Methods
          An alternative for quantifying the probability that the treatment under consideration is cost-effective, which is independent of sample size, is proposed.
        
        
          Results
          Non-parametric methods are given for point and interval estimation. In addition, these methods provide a non-parametric estimator and confidence interval for the incremental cost-effectiveness ratio. An example is provided.
        
        
          Conclusions
          The proposed parameter for quantifying the probability that a new therapy is cost-effective is superior to the acceptability curve because it is not sample size dependent and because it can be interpreted as the proportion of patients who would benefit if given the new therapy. Non-parametric methods are used to estimate the parameter and its variance, providing the appropriate confidence intervals and test of hypothesis.
NCHS Research and Development Survey (RANDS) Round 2 during COVID-19 probability sampled Restricted File

The Research and Development Survey (RANDS) is a series of cross-sectional surveys from probability-sampled commercial survey panels. As part of a special iteration of RANDS that focuses on COVID-19, RANDS during COVID-19 Round 2 is the second round of a three-round survey. The probability sample of RANDS during COVID-19 Round 2 was recruited using NORC at the University of Chicago (NORC)'s AmeriSpeak Panel, and the survey was administered by NORC from August 3, 2020 to August 20, 2020.  The RANDS during COVID-19 Round 2 Probability Sample has a known survey sampling design and can be used to produce nationally and sub-nationally representative estimates
Climate Shield Cutthroat Trout (50% Brook Trout), 1980 (Feature Layer)

This feature class represents the historical (1970-1999) scenario for cutthroat trout, derived from the Climate Shield fish distribution models. These models provide stream-specific probabilistic predictions about the occurrence of juvenile bull trout and cutthroat trout in association with three different scenarios for climate change and brook trout invasions. These datasets indicate all potential cold-water habitats less than 11 degrees Celsius. The attribute fields CT_0BRK - CT_100BRK indicate the probabilities of cutthroat trout occurrence within a cold-water habitat based on the prevalence of brook trout at 0%, 25%, 50%, 75%, or 100% of the sites within a habitat. The probabilities were predicted using the Climate Shield native trout models developed from known species occurrence in greater than 500 cold-water streams. The stream centerlines were based on the National Hydrography Dataset (NHD) but were modified for purposes of modeling and cross-walking to other datasets.
Infective endocarditis: too ill to be operated?

Infective endocarditis remains a disease associated with high mortality in certain groups of patients, with death resulting primarily from central nervous system complications and congestive heart failure. Combined medical and surgical therapy reduces both early and late mortality in complicated cases, especially in patients with valvular dysfunction related to heart failure. In these patients, heart failure is the strongest indication for valve replacement. There are no consensus indications for surgery, however, in the presence of neurological complications or multiple organ failure. Limited data suggest that such surgery is feasible, even in complicated cases necessitating admission to the intensive care unit, and carries an acceptable risk for in-hospital mortality. It is important that critically ill patients with infective endocarditis are enrolled into multicenter studies, using adequate severity scoring systems to assess the impact of clinical and imaging variables on patients' outcome. Until such data are obtained, clinical judgement is still the best tool in decision-making regarding the individual patient.
Gene conversion homogenizes the CMT1A paralogous repeats

Background
          Non-allelic homologous recombination between paralogous repeats is increasingly being recognized as a major mechanism causing both pathogenic microdeletions and duplications, and structural polymorphism in the human genome. It has recently been shown empirically that gene conversion can homogenize such repeats, resulting in longer stretches of absolute identity that may increase the rate of non-allelic homologous recombination.
        
        
          Results
          Here, a statistical test to detect gene conversion between pairs of non-coding sequences is presented. It is shown that the 24 kb Charcot-Marie-Tooth type 1A paralogous repeats (CMT1A-REPs) exhibit the imprint of gene conversion processes whilst control orthologous sequences do not. In addition, Monte Carlo simulations of the evolutionary divergence of the CMT1A-REPs, incorporating two alternative models for gene conversion, generate repeats that are statistically indistinguishable from the observed repeats. Bounds are placed on the rate of these conversion processes, with central values of 1.3 × 10-4 and 5.1 × 10-5 per generation for the alternative models.
        
        
          Conclusions
          This evidence presented here suggests that gene conversion may have played an important role in the evolution of the CMT1A-REP paralogous repeats. The rates of these processes are such that it is probable that homogenized CMT1A-REPs are polymorphic within modern populations. Gene conversion processes are similarly likely to play an important role in the evolution of other segmental duplications and may influence the rate of non-allelic homologous recombination between them.
Compound 528565: gamma-Resorcylic acid, TBDMS

Chemical compound data from PubChem database. IUPAC Name: [tert-butyl(dimethyl)silyl] 2,6-bis[[tert-butyl(dimethyl)silyl]oxy]benzoate. Molecular Formula: C25H48O4Si3. Molecular Weight: 496.9. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Compound 528004: Isopentyl 3,5-dinitrobenzoate

Chemical compound data from PubChem database. IUPAC Name: 3-methylbutyl 3,5-dinitrobenzoate. Molecular Formula: C12H14N2O6. Molecular Weight: 282.25. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Patent AT-E401096-T1: [Translated] USE OF HAPTEN-TREATED TUMOR CELLS AND EXTRACTS

Chemical patent from PubChem database. Patent Number: AT-E401096-T1. Title: Combinatorial Chemistry Method. Filing Date: 2006-06-26. Inventors: Kim, Young-Soo, Taylor, Elizabeth. Abstract: A combinatorial chemistry method for generating libraries of chemical compounds is disclosed, enabling rapid identification of lead compounds for drug... IPC Classifications: B01J, C07C, C07D. This patent covers 47 claims related to 4 chemical compounds. Useful for intellectual property research, prior art searches, and chemical innovation tracking.
Low-molecular-weight heparins in the treatment of venous thromboembolism

Venous thromboembolism is a common disease that is associated with considerable morbidity if left untreated. Recently, low-molecular-weight heparins (LMWHs) have been evaluated for use in acute treatment of deep venous thrombosis and pulmonary embolism. Randomized studies have shown that LMWHs are as effective as unfractionated heparin in the prevention of recurrent venous thromboembolism, and are as safe with respect to the occurrence of major bleeding. A pooled analysis did not show substantial differences among different LMWH compounds used, but no direct comparison of the different LMWHs is currently available. Finally, in patients with pulmonary embolism, there is a relative lack of large studies of daily practice. It could be argued that large prospective studies, in patients who were treated with LMWHs from the moment of diagnosis, are needed.
Debate: does it matter how you lower blood pressure?

The evidence base for drug treatment of hypertension is strong. Early trials 
using thiazide diuretics suggested a shortfall in prevention of coronary heart 
disease. The superiority of newer drugs has been widely advocated but trial 
evidence does not support an advantage of beta-blockers, angiotensin converting 
enzyme inhibitors, calcium channel blockers or alpha-blockers for this outcome. 
Even meta-analyses have failed to clarify matters. If this issue is to be 
settled, bigger and better trials of longer duration in high-risk patients are 
needed. Meanwhile, the importance of rigorous blood pressure control using 
multiple drugs has been established. This should be the focus of our attention 
rather than agonising over differences in cause-specific outcomes that may not 
be generalisable to all patient populations.
Compound 529253: Butan-3-one-2-yl butanoate

Chemical compound data from PubChem database. IUPAC Name: 3-oxobutan-2-yl butanoate. Molecular Formula: C8H14O3. Molecular Weight: 158.19. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Public Health Statistics - Tuberculosis cases and average annual incidence rate, Chicago, 2007-2011 - Historical

Note: This dataset is historical only and there are not corresponding datasets for more recent time periods. For that more-recent information, please visit the Chicago Health Atlas at https://chicagohealthatlas.org.

The annual number of new cases of tuberculosis and average annual tuberculosis incidence rate (new cases per 100,000 residents) with corresponding 95% confidence intervals, by Chicago community area, for the years 2007 – 2011.  See the full description at https://data.cityofchicago.org/api/assets/E0205898-C378-4299-97C1-F9F89AAF603C.
Compound 526905: 2-Butoxyethyl 2,2,2-trifluoroacetate

Chemical compound data from PubChem database. IUPAC Name: 2-butoxyethyl 2,2,2-trifluoroacetate. Molecular Formula: C8H13F3O3. Molecular Weight: 214.18. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Compound 528708: 3,4-Dihydrocadalene

Chemical compound data from PubChem database. IUPAC Name: 4,7-dimethyl-1-propan-2-yl-1,2-dihydronaphthalene. Molecular Formula: C15H20. Molecular Weight: 200.32. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
The FFPSA Title IV-E Prevention Program Implementation Updates

The Family First Prevention Services Act (FFPSA) authorized new optional title IV-E funding for certain time-limited prevention services through creation of the title IV-E prevention program. On March 9, 2020, the Children’s Bureau hosted a webinar to provide an update on the implementation of the title IV-E prevention program and to assist title IV-E agencies and their partners developing prevention plans in their jurisdictions.

Metadata-only record linking to the original dataset. Open original dataset below.
Scanning laser Doppler is a useful technique to assess foot cutaneous
		  perfusion during femoral artery cannulation

Background:
          Measurement of cardiac output and extravascular lung water in
				critically ill patients using femoral artery double-indicator dilution involves
				femoral artery catheterization. The potential risk of vascular compromise to
				the limb may be exacerbated in patients receiving vasopressors. The utility of
				scanning laser Doppler flowmetry to measure changes in pedal perfusion
				following catheterization was assessed.
        
        
          Results:
          There were no significant changes in mean occlusion pressures or
				in cutaneous perfusion between either leg or between measurement time points,
				immediately after or 24 h following insertion of the catheters.
        
        
          Conclusions:
          Scanning laser Doppler flowmetry is easily used to assess changes
				in foot perfusion and the effect of interventions that may reduce blood flow to
				the skin of the foot. Femoral artery catheterization for double-indicator
				dilution measurements does not reduce calf occlusion pressures or foot skin
				perfusion in patients receiving vasopressor drugs.
Compound 529437: 2-Oxo-1-methyl-3-isopropylpyrazine

Chemical compound data from PubChem database. IUPAC Name: 1-methyl-3-propan-2-ylpyrazin-2-one. Molecular Formula: C8H12N2O. Molecular Weight: 152.19. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
NNDSS - TABLE 1L. Ehrlichiosis and Anaplasmosis, Ehrlichia ewingii infection to Giardiasis

NNDSS - TABLE 1L. Ehrlichiosis and Anaplasmosis, Ehrlichia ewingii infection to Giardiasis - 2022. In this Table, provisional cases* of notifiable diseases are displayed for United States, U.S. territories, and Non-U.S. residents.

Notes:

•	These are weekly cases of selected infectious national notifiable diseases, from the National Notifiable Diseases Surveillance System (NNDSS). NNDSS data reported by the 50 states, New York City, the District of Columbia, and the U.S. territories are collated and published weekly as numbered tables available at https://www.cdc.gov/nndss/data-statistics/index.html. Cases reported by state health departments to CDC for weekly publication are subject to ongoing revision of information and delayed reporting. Therefore, numbers listed in later weeks may reflect changes made to these counts as additional information becomes available. Case counts in the tables are presented as published each week. See also Guide to Interpreting Provisional and Finalized NNDSS Data at https://www.cdc.gov/nndss/docs/Readers-Guide-WONDER-Tables-20210421-508.pdf.
• Notices, errata, and other notes are available in the Notice To Data Users page at https://wonder.cdc.gov/nndss/NTR.html.
•	The list of national notifiable infectious diseases and conditions and their national surveillance case definitions are available at https://ndc.services.cdc.gov/. This list incorporates the Council of State and Territorial Epidemiologists (CSTE) position statements approved by CSTE for national surveillance.

Footnotes:

*Case counts for reporting years 2021 and 2022 are provisional and subject to change. Cases are assigned to the reporting jurisdiction submitting the case to NNDSS, if the case's country of usual residence is the U.S., a U.S. territory, unknown, or null (i.e. country not reported); otherwise, the case is assigned to the 'Non-U.S. Residents' category. Country of usual residence is currently not reported by all jurisdictions or for all conditions. For further information on interpretation of these data, see https://www.cdc.gov/nndss/docs/Readers-Guide-WONDER-Tables-20210421-508.pdf.
†Previous 52 week maximum and cumulative YTD are determined from periods of time when the condition was reportable in the jurisdiction (i.e., may be less than 52 weeks of data or incomplete YTD data).
U: Unavailable — The reporting jurisdiction was unable to send the data to CDC or CDC was unable to process the data.
-: No reported cases — The reporting jurisdiction did not submit any cases to CDC.
N: Not reportable — The disease or condition was not reportable by law, statute, or regulation in the reporting jurisdiction.
NN: Not nationally notifiable — This condition was not designated as being nationally notifiable.
NP: Nationally notifiable but not published.
NC: Not calculated — There is insufficient data available to support the calculation of this statistic.
Cum: Cumulative year-to-date counts.
Max: Maximum — Maximum case count during the previous 52 weeks.
Desloratadine

Desloratadine Oral Solution is a prescription antihistamine that helps relieve allergy symptoms like runny nose, sneezing, and itchy eyes. Each mL contains 0.5 mg of desloratadine and is taken by mouth. Manufactured by INA Pharmaceutics, Inc. under FDA application ANDA202936. This information was generated using AI and is provided for informational and research purposes only.
Vasopressin-dependent flank marking in golden hamsters is suppressed by drugs used in the treatment of obsessive-compulsive disorder

Background
          Alterations in arginine vasopressin regulation and secretion have been proposed as one possible biochemical abnormality in patients with obsessive-compulsive disorder. In golden hamsters, arginine vasopressin microinjections into the anterior hypothalamus trigger robust grooming and flank marking, a stereotyped scent marking behaviors. The intensity and repetition of the behaviors induced by arginine vasopressin is somewhat reminiscent of Obsessive Compulsive Disorder in humans. The present experiments were carried out to test whether pharmacological agents used to alleviate obsessive compulsive disorder could inhibit arginine vasopressin-induced flank marking and grooming.
        
        
          Results
          Male golden hamsters were treated daily for two weeks with either vehicle, fluoxetine, clomipramine, or desipramine (an ineffective drug), before being tested for arginine vasopressin-induced flank marking and grooming. Flank marking was significantly inhibited in animals treated with fluoxetine or clomipramine but unaffected by treatment with desipramine. Grooming behavior was not affected by any treatment.
        
        
          Conclusion
          These data suggest that arginine vasopressin-induced flank marking may serve as an animal model for screening drugs used in the control of Obsessive Compulsive Disorder.
Physical Abuse Treatment Outcome Project: Application of Parent-Child Interaction Therapy (PCIT) to Physically Abusive Parents

This project was a randomized clinical trial designed to test the efficacy and sufficiency of Parent-Child Interaction Therapy (PCIT) in preventing re-reports of physical abuse among physically abusive parents entering the child welfare system.  One hundred ten physically abusive parents and their abused children were randomly assigned to one of three intervention conditions:  1) A modified PCIT-based parenting program, 2) The same modified PCIT-based program plus individualized wrap-around services, and 3) a community parenting group program that is representative of current standard care in the field.  Pre- and post-test measures of the family were taken.  Areas of assessment included depression, severity of abuse and neglect, internalizing and externalizing problem behaviors, child abuse potential, parent drug and alcohol disorders, parent-child interaction, parent and child intelligence, child’s perception of parent behaviors, and parent’s willingness to change behavior.  A demographics questionnaire was also administered and a review of child maltreatment reports was conducted.

Investigators: Mark Chaffin, Ph.D.

University of Oklahoma Health Sciences Center, Oklahoma City, OK